A patient diagnosed with NSCLC with advanced CIP after atezolizumab treatment is noted to have escalated interleukin-6 (IL-6) and C-reactive protein levels compared to baseline levels [16]. This evidence concerns the gene IL6 and hereditary sensory and autonomic neuropathy.